Probing of New Polymer-Based Microcapsules for Islet Cell Immunoisolation

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Immunology

Background:

• Islet allotransplantation is a potential therapy for type 1 diabetes but faces challenges like donor scarcity and the need for immunosuppression.
• Microencapsulation of islets in polymer-coated alginate microcapsules is a key strategy for immune protection and maintaining cell viability.

Purpose of the Study:

• To introduce and evaluate Poly [2-(methacryloyloxy)ethyl]trimethylammonium chloride (PMETAC) as an innovative coating for alginate microcapsules for islet encapsulation.
• To assess the stability and cytotoxicity of alginate-PMETAC-alginate microcapsules for islet immunoisolation.
• To determine the optimal PMETAC concentration for microcapsule fabrication.

Main Methods:

• Fabrication of alginate-PMETAC-alginate microcapsules with varying PMETAC concentrations (0.01% to 1%).
• Comprehensive evaluation of microcapsule stability, including osmotic, thermal, and culture condition stability.
• Assessment of microcapsule cytotoxicity and permeability.
• Evaluation of encapsulated islet viability and functional activity.

Main Results:

• Microcapsules coated with 0.4% PMETAC demonstrated optimal stability and appropriate permeability.
• The alginate-PMETAC-alginate microcapsules showed no significant cytotoxicity.
• Encapsulated islets maintained viability and functional activity.
• The 0.4% PMETAC coated microcapsules are suitable for further preclinical animal trials.

Conclusions:

• The novel alginate-PMETAC-alginate microencapsulation system offers enhanced biocompatibility and durability for islet immunoisolation.
• The 0.4% PMETAC concentration provides a promising balance of stability, permeability, and islet viability.
• This cost-effective and simplified approach holds potential for increasing the clinical applicability of islet transplantation for type 1 diabetes.